| Overview |
| bs-12023R-Cy5.5 |
| GPR102/TAAR8 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Cow, Sheep, Pig, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human G protein coupled receptor 102 |
| 51-150/342 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| G protein coupled receptor 102; G-protein coupled receptor 102; GPR102; TA5; TAAR8; TAAR8_HUMAN; TaR-5; TaR-8; TAR5; Trace amine assiciated receptor 8; Trace amine receptor 5; Trace amine receptor 8; Trace amine-associated receptor 8; TRAR5; GPCR GPR102. |
| Trace amines are endogenous molecules structurally related to classical biogenic amines that are linked to psychiatric conditions. A family of G-protein coupled receptors referred to as trace-amine-associated receptors (TAAR) are activated by trace amines and are present in very low levels in mammalian tissue. TaRs contain several structural features that are similar to the rhodopsin -adrenergic receptor superfamily, including the positions of the seven transmembrane regions that provide common ligand-binding pockets as well as the short N- and C-terminal domains. TAAR proteins are potential targets for drugs of abuse, such as amphetamine and MDMA, as well as neuropsychiatric disorders including schizophrenia, depression, and attention deficit disorder. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz